STAT+: Johnson & Johnson advances IBD therapy, despite trial miss

A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.

More from STAT

STAT+: Top lawmaker takes aim at doctor lobby, linking AMA’s billing codes to fraud fight

STAT·4

Opinion: The cruise ship hantavirus outbreak is a warning sign to the U.S.

STAT·5

Opinion: The ‘brain drain’ narrative about health professionals misses half of the story

STAT·4

Opinion: Mifepristone court ruling makes drug development riskier for everyone

STAT·12

Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies

STAT·5

Pump the brakes on AI, buddy; and deposition deadlock

STAT·9